Market Place
Sourcing Support
BioLineRx to Present Motixafortide Data for Sickle Cell at ASH 2024
05 Nov 2024 //
PR NEWSWIRE
BioLineRx Reports Q2 2024 Results And Recent Updates
15 Aug 2024 //
PR NEWSWIRE
BioLineRx to Report Second Quarter 2024 Results on August 15, 2024
08 Aug 2024 //
PR NEWSWIRE
BioLineRx announces trial pact with St. Jude Children`s Research Hospital
03 Jun 2024 //
PHARMABIZ
BioLineRx Announces Clinical Trial Pact With St Jude`s For Motixafortide
30 May 2024 //
PR NEWSWIRE
BioLineRx: Q1 2024 Financials, Corporate & Portfolio Updates Reported
28 May 2024 //
PR NEWSWIRE
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
22 May 2024 //
PR NEWSWIRE
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
17 May 2024 //
PR NEWSWIRE
BioLineRx presents economic model data for APHEXDA® at ISPOR 2024
06 May 2024 //
PR NEWSWIRE
BioLineRx Presents Apheresis Center Efficiency Data on APHEXDA®
17 Apr 2024 //
PR NEWSWIRE
BioLineRx Accesses Second Tranche of $20M Financing
10 Apr 2024 //
PR NEWSWIRE
BioLineRx Announces $6 Million Registered Direct Offering
01 Apr 2024 //
PR NEWSWIRE
BioLineRx Reports 2023 Financial Results
26 Mar 2024 //
PR NEWSWIRE
IM Cannabis to Report Fourth Quarter and Full Year 2023 Financial Results
20 Mar 2024 //
PR NEWSWIRE
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
20 Mar 2024 //
PR NEWSWIRE
BioLineRx Strengthens Intellectual Property Estate
04 Mar 2024 //
PR NEWSWIRE
BioLineRx Announces First Patient Dosed in Ph 2 Trial Evaluating Motixafortide
28 Feb 2024 //
PR NEWSWIRE
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA
16 Feb 2024 //
PR NEWSWIRE
BioLineRx Announces First Patient Dosed in Ph 1 Trial Evaluating Motixafortide
21 Dec 2023 //
PR NEWSWIRE
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023
13 Nov 2023 //
PR NEWSWIRE
BioLineRx Entered Agreement with Motixafortide in Asia, Advised by MSQ Ventures
31 Oct 2023 //
PR NEWSWIRE
BioLineRx Announces Data from Phase 2 Clinical Trial with Motixafortide
28 Sep 2023 //
PR NEWSWIRE
BioLineRx Announces Acceptance of Presentation on Ph 2 Trial with Motixafortide
19 Sep 2023 //
PR NEWSWIRE
BioLineRx’s Aphexda approved to aid stem cell transplants
12 Sep 2023 //
ENDPTS
BioLineRx Announces FDA Approval of APHEXDA for Hematopoietic Stem Cells
11 Sep 2023 //
PR NEWSWIRE
BioLineRx to Report Second Quarter 2023 Results on August 30, 2023
22 Aug 2023 //
PR NEWSWIRE
BioLineRx Announces Initiation of Phase 2 Trial in First Line Metastatic Pancreatic Cancer
17 Jul 2023 //
PR NEWSWIRE
BioLineRx Reports 1Q 2023 FYR and Recent Corporate and Portfolio Updates
24 May 2023 //
PR NEWSWIRE
BioLineRx to Report First Quarter 2023 Results on May 24, 2023
17 May 2023 //
PR NEWSWIRE
BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
25 Apr 2023 //
PR NEWSWIRE
BioLineRx Announces Publication in Nature Medicine of its GENESIS Ph3 Trial
17 Apr 2023 //
PR NEWSWIRE
BioLineRx Reports Financial Results and Recent Corporate and Portfolio Updates
22 Mar 2023 //
PR NEWSWIRE
BioLineRx to Report 2022 Annual Financial Results on March 22, 2023
15 Mar 2023 //
PR NEWSWIRE
BioLineRx Announces Collaboration with Washington University School of Medicine
06 Mar 2023 //
PR NEWSWIRE
BioLineRx Announces Results from Ph1/2a Study of Invg Anti-Tumor Vaccine AGI-134
20 Dec 2022 //
PR NEWSWIRE
BioLineRx Reports Third Quarter 2022 Financial Results and Corporate Updates
15 Nov 2022 //
PRNEWSWIRE
BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA
10 Nov 2022 //
PRNEWSWIRE
BioLineRx to Report Third Quarter 2022 Results on November 15, 2022
10 Nov 2022 //
PRNEWSWIRE
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
04 Nov 2022 //
PRNEWSWIRE
BioLineRx to Present on Cost-Effectiveness of Motixafortide in Myeloma
03 Nov 2022 //
PRNEWSWIRE
BioLineRx Announces U.S. Commercialization Plan for APHEXDA
27 Sep 2022 //
PRNEWSWIRE
BioLineRx Announces $15 Million Registered Direct Offering
19 Sep 2022 //
YAHOO
BioLineRx Announces Submission of NDA to FDA for Motixafortide
12 Sep 2022 //
PRNEWSWIRE
BioLineRx Reports Second Quarter 2022 Financial Results
16 Aug 2022 //
PRNEWSWIRE
BioLineRx, GenFleet Enters Co-Development Agreement for Motixafortide in PDAC
29 Jun 2022 //
PRNEWSWIRE
BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics in PDAC
28 Jun 2022 //
PRNEWSWIRE
BioLineRx Appoints Commercial Strategy and Operations Veteran H. W. May as CCO
16 Jun 2022 //
PRNEWSWIRE
BioLineRx Reports Q1 2022 Financial Results
11 May 2022 //
PRNEWSWIRE
BioLineRx to Report First Quarter 2022 Results on May 11, 2022
05 May 2022 //
PRNEWSWIRE
BioLineRx to Report 2021 Annual Results on March 16, 2022
10 Mar 2022 //
PRNEWSWIRE
BioLineRx Shows Results from Motixafortide + G-CSF to Plerixafor + G-CSF Study
03 Mar 2022 //
PRNEWSWIRE
BioLineRx Completes Enrollment of Phase 1/2a Study of AGI-134 in Solid Tumors
24 Jan 2022 //
PRNEWSWIRE
BioLineRx Announces Successful Completion of Pre-NDA Meeting for Motixafortide
18 Jan 2022 //
PRNEWSWIRE
BioLineRx Presents Data from Pivotal GENESIS Trial of Motixafortide plus
17 Dec 2021 //
TRIALSITENEWS
BioLineRx Reports Q3 2021 Financial Results and Provides Corporate Update
18 Nov 2021 //
PRNEWSWIRE
BioLineRx to Report Third Quarter 2021 Results on November 18, 2021
12 Nov 2021 //
PRNEWSWIRE
BioLineRx Announces an Oral Presentation & Three Poster Presentations at the ASH
04 Nov 2021 //
PRNEWSWIRE
BioLineRx Announces Positive Results from Pharmacoeconomic Study Motixafortide
13 Oct 2021 //
PRNEWSWIRE
BioLineRx shares rise 8% after Motixafortide study results
13 Oct 2021 //
SEEKINGALPHA
BioLineRx Reports Second Quarter 2021 Financial Results and Corporate Updates
18 Aug 2021 //
PRNEWSWIRE
